What guidance did Orasure Technologies's management provide for the next earnings period?

What were the key takeaways from Orasure Technologies’s earnings call?

Did Orasure Technologies beat or miss consensus estimates last quarter?

What is the revenue and EPS growth rate for Orasure Technologies year over year?

What is Orasure Technologies's gross profit margin?

What were the key takeaways from Orasure Technologies's earnings call?

What is Orasure Technologies's latest dividend and current dividend yield?

What factors drove the changes in Orasure Technologies's revenue and profit?

- **Revenue Performance**: Q3 core revenue $27 million, with Diagnostics and Sample Management stable amid market challenges.
- **Strategic Acquisition**: BioMedomics adds Sickle SCAN, targeting underserved markets with potential for $1-3 million annual revenue growth.
- **Cost Efficiency**: Improved gross margin (43.5%) and disciplined OpEx, enabling $10 million Q4 innovation investment.
- **Pipeline Momentum**: Sherlock CT/NG submission expected in late 2025, alongside proteomics and STI product launches.
- **Financial Strength**: $216 million cash, no debt, and disciplined capital deployment.

**【CEO Summary Section】**
- **Q3 2025 Financials**: Total revenue of $27.1 million, with core revenue at $27.0 million. Diagnostics contributed $14.5 million, and Sample Management $10.3 million.
- **International Diagnostics**: Anticipated 20% revenue decline in 2025 due to inventory challenges, with BioMedomics acquisition adding Sickle SCAN for underserved markets.
- **U.S. Diagnostics**: Expansion into non-public health markets (e.g., urgent care, correctional facilities) and renewal of Together Take Me Home program, adding $1.8 million in Q4.
- **Sample Management**: Flat year-over-year revenue but poised for growth in 2026; collaboration with ENDO 1000 project for endometriosis research.
- **Innovation Pipeline**: Launch of HEMAcollect PROTEIN for proteomics, Colli-Pee for STI testing, and Sherlock CT/NG platform in late 2025/early 2026.

**【CFO Financial Commentary】**
- **Q3 Financials**: GAAP operating loss of $16.1 million, non-GAAP loss of $12.7 million. Gross margin 43.5% (44.2% non-GAAP), driven by lower scrap costs.
- **Balance Sheet**: $216 million cash, no debt. $5 million share repurchase and $10 million Q4 innovation investment (Sherlock platform).
- **Q4 Guidance**: Revenue $25-28 million, lower gross margin due to international mix.

**【Q&A Highlights】**
- **BioMedomics Acquisition**: $4 million upfront, potential contingent consideration. Expected to be cash flow breakeven with attractive ROI via OTI's existing channels.
- **Cost Management**: Lower scrap expenses and efficient OpEx allocation, with core business breakeven and innovation-focused spending.
- **In-Sourcing Impact**: No lingering costs; operational efficiencies maintained.


OSUR

OSUR fundamentals

You can ask Aime